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loss.  Conclusion: Poor SRH shortly after transplantation in-
dicates an increased risk of mortality and graft loss at up to 
10 years’ follow-up. SRH could be an inexpensive and reliable 
indicator for starting diagnostic and/or treatment strategies. 
The usefulness of SRH compared to other global clinical 
measures predicting mortality and graft loss should also be 
studied. 
 
Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Self-rated health (SRH) is an independent predictor of 
mortality in patients with end-stage renal disease (ESRD) 
on chronic dialysis  [1] . Persons with poor SRH have a 
higher mortality risk compared with those with excellent 
SRH, even after controlling for a range of demographic 
and clinical variables  [1, 2] . Previous studies have also 
shown that physical, psychological and total scores of 
health-related quality of life were significantly correlated 
with increased risks of ESRD and death in patients with 
chronic kidney disease, independent of comorbidity fac-
tors  [3, 4] .
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 Abstract 
 Background: This study explored whether self-rated health 
(SRH) shortly after kidney transplantation (KT) predicts mor-
tality and graft loss at up to 10 years’ follow-up.  Methods: A 
total of 276 patients shortly after successful KT were inter-
viewed. SRH was measured using the first item of the SF-36 
questionnaire and divided into three tertiles: poor, average 
and excellent health. Clinical data were retrieved from med-
ical records. Cox regression was used to identify whether dif-
ferent levels of SRH predicted mortality and graft loss in 
transplant recipients. The observation period was up to 10 
years.  Results: Poor SRH (HR 11.1, p  ! 0.001), average SRH (HR 
4.21, p  ! 0.05), estimated glomerular filtration rate (HR 0.26, 
p  ! 0.05) and age (HR 1.04, p  ! 0.05) were significantly asso-
ciated with mortality. Similarly, poor SRH (HR 6.4, p  ! 0.001), 
average SRH (HR 3.6, p  ! 0.05), new-onset diabetes mellitus 
after KT (HR 3.3, p  ! 0.05) and chronic renal allograft dysfunc-
tion (HR 3.7, p  ! 0.00) were significantly associated with graft 
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 The medical predictors of mortality are also known. A 
study by Desai and co-workers  [5] has shown that cardio-
vascular and inflammatory markers were predictors of 
mortality and might have important implications for risk 
stratification in the ESRD population. Other studies have 
demonstrated the associations between infections, graft 
rejections, donor and recipient factors with increased 
mortality and graft loss in kidney transplantation (KT) 
recipients  [6–9] . Ravindran et al.  [10] explored the idea 
that new-onset diabetes mellitus after transplantation 
was a well-recognized complication of solid organ trans-
plantation associated with higher patient mortality and 
graft loss.
 Many studies in ESRD, including those after trans-
plantation, have shown medical factors to be associated 
with mortality and graft loss  [6–10] . Moreover, Novak et 
al.  [11] showed that depressive symptoms were an inde-
pendent predictor of mortality-censored graft loss in pa-
tients after KT. Surprisingly, we found no studies on SRH 
as a predictor of mortality or graft loss in KT recipients.
 The aim of this prospective observation study is to ex-
plore whether SRH in an early period after KT predicts 
mortality and graft loss at up to 10 years’ follow-up.
 Methods 
 Sample and Procedure 
 A total of 362 consecutive patients who underwent KT between 
January 2001 and January 2011 at the Transplant Centre of Kosice 
in the eastern region of Slovakia were enrolled in the study. The 
baseline examination of the participants occurred between the 
third and twelfth month after successful KT. The first 3 months 
after KT are usually considered to be the most problematic period 
connected to dramatic changes, increased morbidity and even 
mortality  [12] . Furthermore, improvement in self-perceived health 
most often occurs during the first 2 years after KT  [13] . Before the 
first 3 months after KT, 9 (2.5%) patients were not included be-
cause 3 (0.8%) of them had died and 6 (1.7%) had lost their trans-
planted kidney. The exclusion criteria were the presence of mental 
retardation, acquired cognitive impairments, severe dementia or 
other psychiatric diseases mentioned in the medical record. After 
the exclusion of 1 (0.3%) patient because of the exclusion criteria, 
a total of 352 KT recipients after successful transplant surgery were 
invited to participate. Of those, 34 (9.7%) refused to participate, 31 
(8.8%) did not return the questionnaire, and 11 (3.1%) provided 
questionnaire with missing data, resulting in a total of 276 patients 
(an effective response rate of 78.4%) at the start of the study.  Figure 
1 presents more detailed information on participants.
 Patients provided information about sociodemographic vari-
ables and filled in the questionnaire. All participants were inter-
viewed during regular outpatient clinical visits by trained per-
sonnel independent of the transplant team. Medical data were 
retrieved from medical records at the same time as sociodemo-
graphic data and data of SRH.
 Only patients who signed an informed consent prior to the 
study were included. The local ethics committee in Kosice ap-
proved the study.
 Measures 
Sociodemographic data included age, gender and education. 
Age was treated as a continual variable. We categorized education 
into elementary (primary school, completed or not), apprentice-
ship (completed, or not-completed secondary school), secondary 
(completed, or not-completed university) and university (com-
pleted).
 SRH was measured using the first question of the Short Form 
Health Survey (SF-36)  [14] . The answer options 1 (poor), 2 (fair), 
3 (good), 4 (very good) and 5 (excellent) were transformed into a 
standard scale from 0 (poor health) to 100 (excellent health) in 
which the higher scores indicate a better health status  [14] . This 
scale was then categorized into tertiles: scores 0–30 (fair and poor) 
were categorized as ‘poor health’; 31–60 (good) as ‘average health’, 
and 61–100 (excellent and very good) as ‘excellent health’  [15] . The 
validity and reliability of the first item of the SF-36 has been con-
firmed in patients with renal disease, including those after KT 
 [16–18] .
 Clinical data were retrieved from medical files. These includ-
ed serum creatinine, previous duration of dialysis (in years), pri-
mary kidney diagnosis, source of transplanted kidney, function 
immediately after KT, comorbidity, the current and rejection im-
munosuppressive treatment, acute rejection episodes, chronic re-
nal allograft dysfunction, uroinfection, which included pyelone-
phritis, comorbidities and diagnosis of graft loss, and mortality. 
The estimated glomerular filtration rate (eGFR) was calculated 
using the CKD-EPI formula  [19] . Acute rejection episodes and 
chronic renal allograft dysfunction were diagnosed from biopsy 
according to the Banff 2009 update of diagnostic categories for 
renal allograft biopsies  [20] .
 Statistical Analysis 
 The Mann-Whitney U test and   2 test were used to test the 
differences between respondents and non-respondents. Fre-
quencies, means and standard deviations were calculated for the 
sample description. Both tests were used to identify the associa-
tion between the dependent variables (mortality and graft loss), 
and the other variables: age, gender, education, SRH categorized 
into tertiles (excellent SRH – reference category), eGFR at base-
line, uroinfection (pyelonephritis included), number of acute re-
jection episodes, chronic renal allograft dysfunction, source of 
transplanted kidney, cardiovascular disease – coronary artery 
disease, cardiac failure, myocardial infarction and categories of 
diabetes mellitus (no diabetes mellitus – reference category, al-
ready existing diabetes mellitus and new-onset diabetes mellitus 
after transplantation). Cox regression (conditional LR method) 
was performed in order to identify the predictors of mortality 
(censored for graft loss) and predictors of graft loss. The inde-
pendent variables in both Cox regression models were all vari-
ables with p  ! 0.1 in Mann-Whitney U test and   2 test, as appro-
priate. Harrell’s C-statistic and Somers’ D were calculated for 
both models (model for mortality and model for graft loss). The 
Statistical Package for the Social Science (SPSS, Inc., Chicago, 
Ill., USA) version 18.0.3 and STATA/SE 11.1 were used for statis-
tical analyses.
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 Results 
 No significant differences were found between re-
spondents and non-respondents regarding age and gen-
der. Also, no significant differences were found between 
those who provided complete and incomplete data in age, 
gender, mortality and graft loss. The observation period 
was up to 10 years (mean 5.8  8 2.7) of follow-up; the 
mean period for poor SRH was 4.5  8 0.2 years, for aver-
age SRH 6.5  8 0.2 years and for excellent SRH 6.6  8 0.4 
years. The mean period between transplantation and 
mortality for poor SRH was 3.8  8 1.5 years, for average 
SRH 6.2  8 3.5 years and for excellent SRH 7.2  8 2.6 
years. The mean period between transplantation and 
graft loss for poor SRH was 4.2  8 2.3 years, for average 
SRH 5.6  8 1.5 years and for excellent SRH 7.3  8 1.7. 
During the observation period, 40 patients with poor 
SRH (39.2%) died and 31 (30.4%) lost their transplanted 
kidney; 11 with average SRH (9.0%) died and 20 (16.4%) 
lost their graft and 2 with excellent SRH (3.8%) died and 
3 (5.8%) lost their graft.  Table 1 displays detailed informa-
tion about the characteristics of the sample (n = 257).
 The Mann-Whitney U test showed that age (p  ! 
0.001) and eGFR (p  ! 0.001) were associated with mor-
tality. Age (p  ! 0.001), eGFR (p  ! 0.001), and the number 
of acute rejection episodes (p  ! 0.05) were associated 
with graft loss. The   2 test was performed in order to 
identify factors associated with mortality and graft loss, 
and the findings were that SRH (  2 = 45.2; p  ! 0.001) 
and cardiac failure (  2 = 2.7; p = 0.1) were associated 
with mortality, while SRH (  2 = 15.9; p  ! 0.001), chron-
ic renal allograft dysfunction (  2 = 42.7; p  ! 0.001), and 
diabetes (  2 = 4.5; p  ! 0.1) were associated with graft 
loss. These associations are marked in  table 1 , and the 
mentioned variables were used as independent factors in 
both Cox regression models (model 1 for mortality and 
model 2 for graft loss).
 Acute rejection episodes and cardiac failure were not 
predictors associated with mortality and graft loss in ei-
ther Cox regression model. For mortality, Harrell’s C-sta-
tistic remitted 0.88 and Somers’ D 0.75. Poor (HR 11.1, 
95% CI 4.22; 29.04, p  ! 0.001) and average (HR 4.21, 95% 
CI 1.3; 13.71, p  ! 0.038) SRH contributed significantly to 
this model, as did eGFR (HR 0.98, 95% CI 0.96; 1.0, p  ! 
0.021) and age (HR 1.04, 95% CI 1.0; 1.09, p  ! 0.03). Re-
garding this, the risk of death was increased by 4% for 
each year of age; on the other hand, the risk of death was 
decreased by 2% for each 1 ml/min/1.73 m 2 eGFR ( ta-
 
Patients invited at baseline after KT (n = 352) 
Transplanted patients (n = 362) 
Patients responded at baseline (n = 276, RR = 78.4%) 
Patients lost their transplanted kidney
before follow-up (n = 54, 19.6%) 
Patients excluded by exclusion criteria (n = 1)
Patients refused to participate (n = 34)









Patients died before the first 3 months
after KT (n = 3) 
Patients lost their transplanted kidney before the first 3 months
after KT (n = 6) 
Patients did not return questionnaires
(n = 31)
Patients died with functioning kidney
before follow-up (n = 53, 19.2%) 
Patients alive with functioning kidney
at follow-up (n = 169, 61.2%) 
 Fig. 1. Flow-chart diagram of the participants. RR = Response rate; n = number; KT = kidney transplantation. 
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Age 48.27812.34 * **
G ender male 164 (59.4)
female 112 (40.6)




SRH 49.481.56 * **
Category of SRH poor 102 (37.0) * **
average 122 (44.2) * **
excellent 52 (18.8) * **
Duration on dialysis before KT, years 3.6683.04
Primary diagnosis of kidney failure glomerulonephritis 98 (35.5)
tubulointerstitial nephritis 65 (23.6)
vascular disease 26 (9.4)
polycystic kidneys adult type 25 (9.1)
diabetic nephropathy 18 (6.5)
other/unknown 44 (15.9)
Source of transplanted kidney deceased donor 262 (94.9)
living donor 14 (5.1)
Function immediately after KT immediate 157 (56.88)
delayed 119 (43.12)
Acute rejection episodes 93 (33.7) **
Type of rejection treatment steroids 72 (27.9)
antithymocyte globulin 10 (3.6)
plasmapheresis 6 (2.2)
plasmapheresis + i.v. immunoglobulin 5 (1.8)
Chronic renal allograft dysfunction 42 (15.2) **
Uroinfection 84 (30.4)





eGFR (ml/min/1.73 m2) at baseline 58.8819.8 * **
Comorbidities coronary artery disease 78 (28.3)
cardiac failure 72 (26.1) *
myocardial infarction 17 (6.2)
hypertension 226 (81.9)
diabetes mellitus identified before KT 18 (6.5)
new-onset diabetes mellitus after transplantation 17 (6.2) **
chronic kidney disease-mineral bone disorder 160 (58.0)
other comorbidities: ≥2 9 (3.3)
Diagnosis of graft loss acute rejection episodes 5 (9.3)
chronic renal allograft dysfunction 16 (29.6)
uroinfections 14 (25.9)
others/unknown 19 (35.2)
Diagnosis of mortality acute myocardial infarction 25 (47.2)
pulmonary disease/pulmonary embolism 7 (13.2)
stroke 3 (5.7)
carcinoma/liver disease 6 (11.3)
others/unknown 12 (22.6)
* A ssociation with mortality (p < 0.1); ** association with graft loss (p < 0.1).
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ble 2 ).  Figure 2 displays the differences in mortality be-
tween poor, average and excellent SRH. For graft loss, 
Harrell’s C-statistic was 0.84 and Somers’ D 0.68. Poor 
(HR 6.43, 95% CI 2.98; 13.85, p  ! 0.001) and average (HR 
3.58, 95% CI 1.26; 10.2, p  ! 0.017) SRH contributed sig-
nificantly to this model, as did chronic renal allograft 
dysfunction (HR 3.71, 95% CI 1.82; 7.6, p  ! 0.001) and 
new-onset diabetes mellitus after transplantation (HR 
3.29, 95% CI 1.16; 9.34, p  ! 0.015). In line with this, chron-
ic renal allograft dysfunction was associated with a 3.7-
fold higher and new-onset diabetes mellitus after trans-
plantation with a 3.3-fold higher risk of graft loss ( ta-
ble  2 ).  Figure 3 displays the differences in graft loss 
between poor, average and excellent SRH.
 Discussion 
 In this study we explored SRH in an early period after 
KT as a predictor of mortality and graft loss in KT re-
cipients at up to 10 years’ follow-up. In addition to SRH, 
age and eGFR were predictors of patient mortality. The 
predictors for graft loss were SRH, chronic renal allograft 
dysfunction and new-onset diabetes mellitus after trans-
plantation. In line with our findings, Kutner and co-
workers  [21] showed that physical functioning might be 
used together with factors in pretransplant recipients to 
prove their potential risk for morbidity, graft loss and 
mortality after KT.
 In the Cox regression model for mortality, we found 
that patients with a higher eGFR had a significantly re-
duced mortality hazard ratio. On the other hand, average 
SRH was associated with a 4-fold higher and poor SRH 
with an 11-fold higher risk of mortality. In the Cox re-
gression model for graft loss, we found that chronic renal 
allograft dysfunction, new-onset diabetes mellitus after 
KT and average SRH were associated with a 3-fold higher 
risk of graft loss, and poor SRH was associated with a 
6-fold higher risk of graft loss. Much like our findings of 
the risk ratio for graft loss, many studies have explored 
the idea that graft rejection and new-onset diabetes mel-
litus increased the graft loss risk ratio  [9, 22] . Surpris-
ingly, cardiovascular disease was not associated with 
mortality or graft loss in our sample, which is probably 
due to underdiagnosis, as we relied on evidence in the 
medical records and did not actively evaluate patients’ 
comorbidity.
 To our knowledge, when searching the literature we 
found no study exploring whether there is an association 
of SRH with mortality and graft loss in KT recipients. 
Tanikella et al.  [23] in their study with 3 years’ follow-up 
explored whether liver-transplanted patients with lower 
self-reported physical quality of life had an increased risk 
of mortality. So far, studies on dialysis patients have es-
tablished a significant connection between poorer SRH 
and higher risk of mortality  [1, 3, 4] . Spiegel et al.  [24] in 
their systematic review explored a close connection be-
tween poor well-being, morbidity and mortality in pa-
tients with ESRD. These findings are in line with our re-
sults. Thus, SRH might reflect several adverse conditions 
and therefore may provide additional information on a 
patient’s risk, independent of demographic, socioeco-
nomic and clinical risk factors for mortality  [15] and graft 
loss.
 Strengths and Limitations 
 The strength of this study is the prospective follow-up 
for 10 years, which enabled us to explore SRH and the 
others factors as predictors of mortality and graft loss af-
ter KT. Moreover, all consecutive patients originating 
from one major transplant center in Slovakia over a num-
ber of years were asked to participate in the study to pre-
vent selection bias.
 Missing data is a limitation of this study; on the other 



















 Fig. 2. Differences in mortality between poor, average and excel-
lent SRH over 10 years. 
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tween respondents and non-respondents, and no differ-
ences in age, gender, mortality and graft loss between re-
cipients who provided complete and incomplete data. 
The variable observation period between minimum and 
maximum (1 and 10 years) is also a limitation. The SRH 
interviews were not conducted immediately after trans-
plantation to prevent false findings due to perioperative 
stress. Therefore, patients who died or lost their trans-
planted kidney before the first 3 months after KT were 
not incorporated into the study. It could be of interest to 
control for a potential effect of pretransplantation SRH, 
as it may predict mortality and graft loss as well. Our 
findings might only be used partially due to their poten-
tial lack of generalizability, as we used data from a single-
center sample.
 Policy Implications 
 SRH could be used as an inexpensive and swift predic-
tor of risky KT recipients. Patients with poor SRH might 
undergo relevant clinical as well as laboratory assessment 
and/or treatment to reduce their high risk of mortality 
and graft loss.
 Recommendations for Further Research 
 Results must be verified in a larger multicenter sample 
to allow for generalization. We could then verify whether 
SRH after KT remains a predictor of mortality and graft 
loss in KT recipients, or whether in a longer period after 
KT other variables become important. Furthermore, the 
pathways between psychological, physical and medical 
determinants associated with SRH, mortality and graft 
loss should be studied.







Model 1 – Mortality (n = 276); Harrell’s C-statistic = 0.88; Somers’ D = 0.75
Age 365.39 0.04 (0.02)* 1.04 1.00; 1.09




2.41 (0.49)*** 11.1 4.22; 29.04
Average 1.44 (0.60)* 4.21 1.30; 13.71
Excellent reference
Model 2 – Graft loss (n = 276); Harrell’s C-statistic = 0.84; Somers’ D = 0.68
Chronic renal allograft dysfunction 398.97 1.31 (0.37)*** 3.71 1.82; 7.60




1.86 (0.39)*** 6.43 2.98; 13.85
Average 1.28 (0.53)* 3.58 1.26; 10.20
Excellent reference



















 Fig. 3. Differences in graft loss between poor, average and excel-
lent SRH over 10 years. 
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 Conclusion 
 Poor and average SRH in an early period after trans-
plantation indicated a higher risk of mortality and graft 
loss at up to 10 years’ follow-up. Poor SRH is associated 
with an 11-fold higher risk of mortality and a 6-fold high-
er risk of graft loss compared to excellent SRH at up to 10 
years’ follow-up. Patients with poor SRH might undergo 
relevant clinical as well as laboratory assessment and/or 
treatment to reduce their high risk of mortality and graft 
loss.
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